Related references
Note: Only part of the references are listed.Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials
Kelong Han et al.
NEURO-ONCOLOGY (2014)
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Mark R. Gilbert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Bevacizumab for Newly Diagnosed Glioblastoma Reply
Olivier L. Chinot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Bevacizumab plus Radiotherapy-Temozolomide for Newly Diagnosed Glioblastoma
Olivier L. Chinot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Detecting an Overall Survival Benefit that Is Derived From Progression-Free Survival
Kristine R. Broglio et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger Stupp et al.
LANCET ONCOLOGY (2009)
Share Paper
